UBS Group’s Quantum Biopharma Class B Subordinate Voting Shares QNTM Stock Holding History

UBS Group’s Portfolio QNTM Stock Details QNTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35K	Buy	7,237 +5,527	+323%	+$24.9K	﹤0.01%	7596
2025 Q4	$12.5K	Sell	1,710 -7,044	-80%	-$76.8K	﹤0.01%	8111
2025 Q3	$144K	Sell	8,754 -37,129	-81%	-$733K	﹤0.01%	6877
2025 Q2	$929K	Buy	45,883 +44,269	+2,743%	+$546K	﹤0.01%	5507
2025 Q1	$12.4K	Buy	+1,614	New	+$9.28K	﹤0.01%	8495
2024 Q3	–	Sell	-478	Closed	-$5.03K	–	10218
2024 Q2	$5.03K	Sell	478 -89	-16%	-$2.17K	﹤0.01%	8032
2024 Q1	$26.4K	Buy	567 +161	+40%	+$8.82K	﹤0.01%	6792
2023 Q4	$24.3K	Buy	+406	New	+$28.6K	﹤0.01%	6984
2021 Q4	–	Sell	-14	Closed	-$1K	–	10810
2021 Q3	$1K	Buy	14 +6	+75%	+$641	﹤0.01%	9271
2021 Q2	$1K	Sell	8 -9	-53%	-$1.04K	﹤0.01%	9203
2021 Q1	$2K	Buy	+17	New	+$2.38K	﹤0.01%	8656
2020 Q4	–	Sell	-75	Closed	-$12K	–	8838
2020 Q3	$12K	Buy	75 +28	+60%	+$5.81K	﹤0.01%	6716
2020 Q2	$12K	Buy	+47	New	+$11K	﹤0.01%	6905

Other funds holding QNTM

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

PTP

Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

AUB

Atlantic Union Bankshares Glen Allen, Virginia $5.21B AUM 19.46% 1-Year Est. Return

UBS Group's QNTM Position: Q1 2026 in Review

UBS Group increased its Quantum Biopharma Class B Subordinate Voting Shares (QNTM) stake by 323% in Q1 2026, buying an estimated $24.9K and bringing the position to 7,237 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #7596.

UBS Group first reported a position in QNTM in Q2 2020 and has held it in 13 quarters since. The position peaked at $929K in Q2 2025. 25 funds tracked by Wall St. Rank hold QNTM as of Q1 2026.

UBS Group held 7,237 shares of Quantum Biopharma Class B Subordinate Voting Shares worth $35K as of Q1 2026.
UBS Group bought 5,527 Quantum Biopharma Class B Subordinate Voting Shares shares in Q1 2026, an estimated $24.9K.
Quantum Biopharma Class B Subordinate Voting Shares made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7596 holding.
UBS Group first reported a position in Quantum Biopharma Class B Subordinate Voting Shares in Q2 2020 and has held it in 13 quarters since.
UBS Group's Quantum Biopharma Class B Subordinate Voting Shares position peaked at $929K in Q2 2025.
25 funds tracked by Wall St. Rank held Quantum Biopharma Class B Subordinate Voting Shares as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.